Arvinas raises $19.25m for novel protein degradation approach
This article was originally published in Scrip
Executive Summary
Arvinas raised $19.25m in a Series A venture funding round and from the state of Connecticut to finance drug candidates that degrade disease-causing proteins, rather than inhibit them, and address targets that have eluded drug developers in the past.